{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:34:42Z","timestamp":1793144082830,"version":"4.5.0"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Summarize recent evidence on the identification and management of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Clinical and subclinical interstitial lung disease (ILD) are frequent extra-articular manifestations of rheumatoid arthritis (RA). Better means of identifying and treating RA-ILD are needed to improve the prognosis, with a median survival of only 3\u20137 years after diagnosis. Several serum biomarkers are currently being evaluated for their ability to detect RA-ILD. Thorough evaluation and multidisciplinary discussion remains the gold standard for establishing the diagnosis of RA-ILD. Management is challenging with most RA disease-modifying antirheumatic drugs (DMARDs) linked to pneumonitis. Methotrexate is typically avoided in clinically significant ILD, although alternative therapies including leflunomide and biologic DMARDs also carry risks in RA-ILD. Antifibrotics appear to slow the progression of ILD, and a large phase II trial exclusively in RA-ILD is underway. In addition, smoking cessation, pulmonary rehabilitation, oxygen therapy, managing comorbidities, and lung transplantation evaluation are vital to improving patient outcomes in RA-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>With little high-quality evidence to guide the management of RA-ILD, multidisciplinary teams with expertise in RA-ILD are highly valuable for diagnosing and treating RA-ILD. Clinical and translational research in RA-ILD is needed to fill the many evidence gaps.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000703","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T07:41:03Z","timestamp":1583480463000},"page":"255-263","source":"Crossref","is-referenced-by-count":71,"title":["Management issues in rheumatoid arthritis-associated interstitial lung disease"],"prefix":"10.1097","volume":"32","author":[{"given":"Bryant R.","family":"England","sequence":"first","affiliation":[{"name":"Division of Rheumatology & Immunology, Department of Internal Medicine, University of Nebraska Medical Center (UNMC)"},{"name":"VA Nebraska-Western Iowa Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hershberger","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, Sleep, & Allergy, Department of Internal Medicine, UNMC, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bmj.2.4583.816","article-title":"Rheumatoid disease with joint and pulmonary manifestations","volume":"2","author":"Ellman","year":"1948","journal-title":"Br Med J"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","article-title":"Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort","volume":"49","author":"Koduri","year":"2010","journal-title":"Rheumatology"},{"issue":"(2 Pt 1)","key":"R4-20230829","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics \u2013 a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000502551","article-title":"Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality","volume":"98","author":"Hyldgaard","year":"2019","journal-title":"Respiration"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12890-016-0269-2","article-title":"Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes","volume":"16","author":"Nurmi","year":"2016","journal-title":"BMC Pulm Med"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1378\/chest.127.6.2019","article-title":"Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.semarthrit.2019.04.005","article-title":"Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"49","author":"Singh","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1800869","DOI":"10.1183\/13993003.00869-2018","article-title":"Predicting outcomes in rheumatoid arthritis related interstitial lung disease","volume":"53","author":"Jacob","year":"2019","journal-title":"Eur Respir J"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"e17088","DOI":"10.1097\/MD.0000000000017088","article-title":"High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities","volume":"98","author":"Salaffi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12890-019-0875-x","article-title":"Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device)","volume":"19","author":"Manfredi","year":"2019","journal-title":"BMC Pulm Med"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/art.40900","article-title":"Malondialdehyde-acetaldehyde adducts and antibody responses in rheumatoid arthritis-associated interstitial lung disease","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.38904","article-title":"Biomarkers of rheumatoid arthritis-associated interstitial lung disease","volume":"67","author":"Chen","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clim.2014.08.004","article-title":"Anticitrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses","volume":"155","author":"Harlow","year":"2014","journal-title":"Clin Immunol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"e98794","DOI":"10.1371\/journal.pone.0098794","article-title":"Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease","volume":"9","author":"Giles","year":"2014","journal-title":"PLoS One"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/rheumatology\/kex520","article-title":"Anticitrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis","volume":"57","author":"Alunno","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann Intern Med"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/art.39226","article-title":"Bronchiectasis is a model for chronic bacterial infection inducing autoimmunity in rheumatoid arthritis","volume":"67","author":"Quirke","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.rmed.2012.03.006","article-title":"Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease","volume":"106","author":"Fischer","year":"2012","journal-title":"Respir Med"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/art.41123","article-title":"Comparative profiling of serum protein biomarkers in rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis","volume":"72","author":"Kass","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3899\/jrheum.171314","article-title":"Rheumatological assessment is important for interstitial lung disease diagnosis","volume":"45","author":"Levi","year":"2018","journal-title":"J Rheumatol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000484055","article-title":"Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the cryobiopsy working group on safety and utility and a call for standardization of the procedure","volume":"95","author":"Hetzel","year":"2018","journal-title":"Respiration"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"160080","DOI":"10.1183\/16000617.0080-2016","article-title":"Oxygen therapy for interstitial lung disease: a systematic review","volume":"26","author":"Bell","year":"2017","journal-title":"Eur Respir Rev"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"e0209069","DOI":"10.1371\/journal.pone.0209069","article-title":"A randomized cross-over trial on the direct effects of oxygen supplementation therapy using different devices on cycle endurance in hypoxemic patients with Interstitial Lung Disease","volume":"13","author":"Edvardsen","year":"2018","journal-title":"PLoS One"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial","volume":"72","author":"Dowman","year":"2017","journal-title":"Thorax"},{"key":"R35-20230829","first-page":"CD006322","article-title":"Pulmonary rehabilitation for interstitial lung disease","author":"Dowman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2016.12.013","article-title":"Survival and outcomes after lung transplantation for nonscleroderma connective tissue-related interstitial lung disease","volume":"36","author":"Courtwright","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.healun.2014.01.858","article-title":"Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation","volume":"33","author":"Yazdani","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 5)","key":"R41-20230829","first-page":"v1","article-title":"Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rdc.2015.08.005","article-title":"Glucocorticoid-induced osteoporosis","volume":"42","author":"Whittier","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/keg466","article-title":"Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis","volume":"43","author":"Saravanan","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and antitumor necrosis factor alpha agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/rheumatology\/kep050","article-title":"Clinical expression of leflunomide-induced pneumonitis","volume":"48","author":"Chikura","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1183\/09031936.02.00267402","article-title":"Sulphasalazine and lung toxicity","volume":"19","author":"Parry","year":"2002","journal-title":"Eur Respir J"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"e000473","DOI":"10.1136\/rmdopen-2017-000473","article-title":"Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic","volume":"3","author":"Druce","year":"2017","journal-title":"RMD Open"},{"key":"R57-20230829","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","author":"Kang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R58-20230829","article-title":"Performance of administrative algorithms to identify interstitial lung disease in rheumatoid arthritis","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4236\/ojra.2012.23011","article-title":"Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia","volume":"2","author":"Matteson","year":"2012","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R61-20230829","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study","author":"Manfredi","year":"2019","journal-title":"Intern Med J"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fernandez-Diaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rcreue.2018.02.003","article-title":"Janus kinase inhibitors as a therapeutic option in rheumatoid arthritis and associated interstitial lung disease. Report of four cases","volume":"26","author":"Saldarriaga-Rivera","year":"2019","journal-title":"Revista Colombiana de Reumatolog\u00eda (English Edition)"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-019-1963-2","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice","volume":"21","author":"Sendo","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3346\/jkms.2002.17.2.270","article-title":"Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report","volume":"17","author":"Chang","year":"2002","journal-title":"J Korean Med Sci"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/39.12.1422","article-title":"Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis","volume":"39","author":"Ogawa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2177\/jsci.31.62","article-title":"A case report of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiple bullae and pneumomediastinum, which was successfully treated with tacrolimus","volume":"31","author":"Ochi","year":"2008","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"R75-20230829","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/resp.13365","article-title":"Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus","volume":"23","author":"Yamano","year":"2018","journal-title":"Respirology"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R77-20230829","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11537460-000000000-00000","article-title":"Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials","volume":"30","author":"Schiff","year":"2010","journal-title":"Clin Drug Investig"},{"key":"R78-20230829","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.1780350802","article-title":"Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"35","author":"Willkens","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R79-20230829","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"R80-20230829","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s12325-019-01086-2","article-title":"The design and rationale of the trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease","volume":"36","author":"Solomon","year":"2019","journal-title":"Adv Ther"},{"key":"R81-20230829","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","article-title":"Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease","volume":"314","author":"Redente","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R82-20230829","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R83-20230829","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ebiom.2018.01.038","article-title":"Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis interstitial lung disease","volume":"28","author":"Jacob","year":"2018","journal-title":"EBioMedicine"},{"key":"R85-20230829","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.chest.2018.07.038","article-title":"Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis","volume":"155","author":"Bedard Methot","year":"2019","journal-title":"Chest"},{"key":"R86-20230829","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14740338.2019.1577820","article-title":"Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies","volume":"18","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"R87-20230829","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R88-20230829","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/acr.24040","article-title":"2019 American College of Rheumatology recommended patient-reported functional status assessment measures in rheumatoid arthritis","volume":"71","author":"Barber","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R89-20230829","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"key":"R90-20230829","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/art.40769","article-title":"Proceedings of the American College of Rheumatology\/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: a multidisciplinary approach to address challenges and opportunities","volume":"71","author":"Fischer","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:11:52Z","timestamp":1693278712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000703","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}